Clinical benefits and risks of phase I oncology trials: experience from a single institution

Authors :: Imran Chaudhary
Swati Goel
Sridhar Mani
M. H. Ghalib
M. Kumar
K. Desai
R. Gollamudi
B. M. Wong
Source :: Journal of Clinical Oncology. 26:6572-6572
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 6572 Background: The majority of published series of phase I oncology trials has reported response rates between 4 to 6 percent. A recent meta-analysis of phase I studies showed a higher response r...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Internal medicine
medicine
Single institution
business
Phase (combat)

Tools